Lev Facher

Washington Correspondent

Lev Facher is a Washington Correspondent for STAT, reporting on the politics of health and life sciences. He has written extensively about the federal government's response to the opioid crisis, the pharmaceutical industry's influence on Capitol Hill, and federally funded biomedical research. Lev earned an economics degree from the University of Michigan, where he worked as managing editor of The Michigan Daily. You can reach him via email at lev.facher@statnews.com and by phone/WhatsApp/Signal at (510)-374-8880.

STAT+ Conversations

STAT+ Conversations: How pharma is influencing the 2020 election

AAMC, the medical school trade association, gave $500,000 to dark-money group in 2018

Pharma is showering Congress with cash, even as drug makers race to fight the coronavirus

Following court ruling, NIH warns drug and device companies to post missing trial data

The drug industry’s new tactic in Washington: calling Trump’s bluff

Liberal group warns that the U.S. is unprepared to distribute a Covid-19 vaccine

Covid-19 relief package likely to include billions more for vaccines, testing

Trump administration unveils executive orders to curb drug prices — but they come with caveats

FDA says opioid labels must include information about naloxone

Many drug companies working on Covid-19 vaccines and treatments are lobbying harder than usual

NIH Director Francis Collins defends Fauci amid White House criticism

What’s next for Anthony Fauci, if the White House continues to sour on him?

Trouble in paradise: The Senate’s bipartisan accord on drug prices is broken, says Grassley

Top U.S. health officials say they were never told to slow down Covid-19 testing, contradicting Trump

As Covid-19 devastates communities of color, the government’s minority health experts are conspicuously quiet

Trump says Covid-19 is ‘dying out.’ Experts fear his dismissiveness could prolong the crisis

Trump administration pledges future Covid-19 vaccines will be free for ‘vulnerable’ Americans

FDA revokes emergency use ruling for hydroxychloroquine, the drug touted by Trump as a Covid-19 therapy